GlassScriptPhysician profile
Christina C Cernik
NPI 1558523605
$2,963.43
in general payments reported to CMS, 2019-2025
27 companies · none reported in 2025
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $561 · 2020: $158 · 2021: $447 · 2022: $517 · 2023: $981 · 2024: $300.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $1,281.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $1,281.14 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Abbvie INC. | $968.97 | 2019-2024 | Skyrizi, Rinvoq |
| Sun Pharmaceutical Industries INC. | $425.38 | 2019-2023 | Ilumya, Winlevi, Absorica Ld |
| Pfizer INC. | $267.23 | 2019-2024 | |
| Novartis Pharmaceuticals Corporation | $189.27 | 2019-2024 | |
| Lilly USA, LLC | $177.12 | 2019-2024 | Taltz |
| E.R. Squibb & Sons, L.L.C. | $110.91 | 2022-2024 | Sotyktu |
| Dermavant Sciences, INC. | $104.12 | 2023 | Vtama |
| Janssen Biotech, INC. | $102.57 | 2019-2023 | Tremfya |
| Amgen INC. | $89.89 | 2021-2024 | Otezla, Enbrel |
| Mayne Pharma Commercial LLC | $59.87 | 2019 | |
| Regeneron Healthcare Solutions, INC. | $57.23 | 2019-2021 | |
| Galderma Laboratories, L.P. | $41.81 | 2019-2020 | |
| Celgene Corporation | $39.31 | 2019 | |
| Genzyme Corporation | $36.74 | 2019-2024 | |
| Incyte Corporation | $33.33 | 2021-2023 | Opzelura |
Show all 27 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Boehringer Ingelheim Pharmaceuticals, INC. | $30.63 | 2023 | Spevigo |
| Arcutis Biotherapeutics, INC. | $30.04 | 2023 | |
| Genentech USA, INC. | $28.39 | 2019 | |
| Dermira, INC. | $25.92 | 2019 | |
| Leo Pharma INC. | $20.48 | 2021 | |
| Ucb, INC. | $20.00 | 2023 | Cimzia |
| Kyowa Kirin, INC. | $19.81 | 2023 | Poteligeo |
| Almirall LLC | $18.82 | 2019 | |
| Dusa Pharmaceuticals, INC. | $17.73 | 2019 | |
| Ortho Dermatologics, A Division of Bausch Health US, LLC | $17.07 | 2022 | |
| Biofrontera INC. | $16.79 | 2019 | |
| Helsinn Therapeutics (U.S.), INC. | $14.00 | 2019 |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Christina Cernik listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.